Successful heart lung transplantation in patient with pulmonary capillary hemangiomatosis: case presentation

   Our observation demonstrates a case of a 40-year-old female with pulmonary arterial hypertension World Health Organization functional class III, who was admitted to NMRC of Cardiology repeatedly due to disease progression including dyspnea worsening, onset of desaturation and chest pain during exertion on riociguat (7.5 mg daily), bosentan (115 mg daily) and selexipag (400 mcg daily) therapy. Computed tomography scan revealed pulmonary capillary hemangiomatosis pattern and the diagnosis was revealed. We performed PAH-specific therapy escalation which resulted in selexipag withdrawal, bosentan dose titration to 250 mg daily with good treatment tolerability. Due to unreleased treatment goals, high-risk status and heart failure progression, the patient was referred to Shumakov National Medical Research Center of Transplantology and Artificial Organs, where successful heart lung transplant was performed in may 2022. The postoperative period elapsed without complication, the patient discharged from hospital and is staying alive in stable condition. Pulmonary capillary hemangiomatosis is a rare cause of pulmonary arterial hypertension with pure prognosis. PAH-specific treatment should be avoided due to increased risk of rapid disease progression and pulmonary oedema. The only one definitive treatment is lung or heart lung transplantation.

1. Chazova I.E., Martynyuk T.V., Valieva Z.S., et al. Eurasian Guidelines for the diagnosis and treatment of pulmonary hypertension. Eurasian Нeart Journal 2020;1:78-122. (In Russ.)]. doi: 10.38109/2225-1685-2020-1-78-122

2. Russian Transplant Society. "Lung transplantation, heart-lung complex transplantation, presence of a transplanted lung, presence of a transplanted heart-lung complex, dying and rejection of a lung transplant, dying and rejection of a heart-lung transplant. Clinical Guidelines. 2020:113 с. (In Russ)

3. López-Meseguer M, Quezada CA, Ramon MA, et al. Lung and heart-lung transplantation in pulmonary arterial hypertension [published correction appears in PLoS One. 2018 Jan 29;13(1):e0192100]. PLoS One. 2017;12(11):e0187811. Published 2017 Nov 21. doi: 10.1371/journal.pone.0187811

4. Eltorky MA, Headley AS, Winer-Muram H, Garrett HE Jr, Griffin JP. Pulmonary capillary hemangiomatosis : a clinicopathologic review. Ann Thorac Surg. 1994 Mar;57(3):772-6. doi: 10.1016/0003-4975(94)90595-9

5. Guzman S, Khan MS, Chodakiewitz Y, Khan M, Chodakiewitz MS, et al. Pulmonary capillary hemangiomatosis: a lesson learned. Autops Case Rep. 2019 Aug 22;9(3):e2019111. doi: 10.4322/acr.2019.111.

6. Chazova I.E., Martynyuk T.V. Pulmonary hypertension. – Moscow. Praktika. 2015;928 p. (In Russ.)

7. Humbert M, Kovacs G, Hoeper MM, et al. ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J 2022;43(38):3618-373. doi: 10.1093/eurheartj/ehac237